Panitumumab
Brand Names: Vectibix
Methodology & AI Transparency ⓘ
Panitumumab Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Supplied in 400 mg/20mL Solution and 100 mg/5mL Solution and manufactured/labeled by Amgen, Inc (NDC 55513-956, 55513-954), Panitumumab operates within intravenous-route epidermal growth factor receptor antagonist treatment algorithms requiring prescription authorization.
- 2 Real-world patient consensus: Zero-PHI community consensus: 85% favorable across 19 logged regimens (Vectibix).
- 3 Typical cash cost range: 30-day cash pricing ranges from $71.28 discount cash to $174.64 walk-in retail (NADAC $1.5500/unit).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Panitumumab: nausea (9.1%), headache (8.5%), dizziness (5.8%).
Ask our AI Specialists anything about Panitumumab
Panitumumab Mechanism, CYP450 Pathways & DailyMed Monograph
Supplied in 400 mg/20mL Solution and 100 mg/5mL Solution and manufactured/labeled by Amgen, Inc (NDC 55513-956, 55513-954), Panitumumab operates within intravenous-route epidermal growth factor receptor antagonist treatment algorithms requiring prescription authorization.
Delivered via 400 mg/20mL Solution and 100 mg/5mL Solution (intravenous-route; NDC 55513-956, 55513-954), Panitumumab mediates epidermal growth factor receptor antagonist physiological effects manufactured/labeled by Amgen, Inc with dose-dependent receptor occupancy and systemic clearance.
Pharmacokinetic profiling of Panitumumab demonstrates an elimination half-life of Elimination kinetics span 5 to 15 hours per Panitumumab clinical pharmacology with Consistent 77%–89% gastrointestinal absorption profile for Panitumumab systemic bioavailability; clearance proceeds via systemic clearance of panitumumab integrates hepatic phase ii conjugation with renal filtration, reaching clinical onset within cmax attained 2–5 hours post-administration of panitumumab.
Titration schedules for Panitumumab (400 mg/20mL Solution → 100 mg/5mL Solution) require excluding confirmed ige-mediated allergy or cutaneous reaction to panitumumab (panitumumab) components; uncompensated hepatic or renal insufficiency incompatible with panitumumab (400 mg/20ml solution) clearance; real-world patient logs highlight nausea (9.1% of reports), headache (8.5% of reports), fatigue (5.8% of reports) alongside a 85.00% Worth-It consensus.
Reconcile eGFR-adjusted medications before escalating Panitumumab in polypharmacy regimens.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Panitumumab dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Panitumumab (Panitumumab) components
- Uncompensated hepatic or renal insufficiency incompatible with Panitumumab (400 mg/20mL Solution) clearance
Logged Side-Effect Incidence (19 Reports)
Panitumumab Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Panitumumab)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Using methods to extend inferences to specific target populations to improve the While extending inferences from study populations to specific targets can improve the precision of estimates in small subgroups, violating key assumptions creates bias for many subgroups of interest. Journal of clinical epidemiology • 2025-05-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39924128 ↗ |
Panitumumab Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.5500/unit (~$46.50/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $174.64 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 19 Anonymous DotMD Community Micro-Logs | $71.28 / mo | View logs ↓ |
Panitumumab Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Panitumumab RxNorm Concept ID | RXN-55513956-3097 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.5500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $174.64 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $71.28 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 85.00% Worth It (19 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Panitumumab Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Panitumumab integrating DailyMed SPL (2026-07-01), CMS NADAC ($1.5500/unit), and 19 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Panitumumab community threads and patient logs by age, biological sex, dosage, and treatment duration.